Sutent 12.5 mg hard capsules, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PAZOPANIB , Sutent 25 mg hard capsules
MK-3475-679
Phase 3 small_molecule active
Quick answer
Sutent 12.5 mg hard capsules, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PAZOPANIB , Sutent 25 mg hard capsules for Locally advanced/metastatic renal cell carcinoma is a Phase 3 program (small_molecule) at Incyte Biosciences Distribution B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Incyte Biosciences Distribution B.V.
- Indication
- Locally advanced/metastatic renal cell carcinoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active